Citi upgrades MacroGenics on positive margetuximab data

|About: ADMA Biologics Inc (ADMA)|By:, SA News Editor

MacroGenics (NASDAQ:MGNX) upgraded to Buy with a $39 (52% upside) price target at Citigroup on positive margetuximab data. Shares up 5% premarket. Price target raised to $26 at Morgan Stanley and $50 at Nomura.

ADMA Biologics (NASDAQ:ADMA) resumed with Buy rating and $10 (260% upside) at H.C. Wainwright.

Subscribe for full text news in your inbox